drugset
drugset / Trial / NCT06644755

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

NCT06644755 ↗

Phase 1 Recruiting 150 enrolled Daiichi Sankyo
NaSequentialOpen-labelTreatment

Summary

This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.

Timeline

Start
2024-11-14
Primary completion
2028-11-30
Completion
2028-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject DS-2243a Unknown — —

Indications

sarcoma